GBG Forschungs GmbH (German Breast Group)

Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer (2025) Conforti F, Nekljudova V, Sala I, Ascari R, Solbach C, Untch M, Denkert C, et al. Journal article Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers. (2025) Häberle L, Erber R, Gaß P, Hein A, Niklos M, Volz B, Hack C, et al. Journal article On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer (2024) Sinn BV, Sychra K, Untch M, Karn T, van Mackelenbergh M, Huober J, Schmitt W, et al. Journal article Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer (2024) Denkert C, Schneeweiss A, Rey J, Karn T, Hattesohl A, Weber KE, Rachakonda S, et al. Journal article Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)] (2024) de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, et al. Journal article Preoperative radiotherapy versus postoperative radiotherapy after neoadjuvant chemotherapy (“NeoRad”) in high-risk breast cancer: a prospective randomized international multicenter phase III trial Präoperative Radiotherapie versus postoperative Radiotherapie nach neoadjuvanter Chemotherapie („NeoRad“) beim Hochrisikomammakarzinom: eine prospektive, randomisierte, internationale multizentrische Phase-III-Studie (2024) Matuschek C, Jazmati D, Krug D, Corradini S, Fehm T, Ruckhäberle E, Kühn T, et al. Journal article An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials (2024) Jank P, Karn T, van Mackelenbergh M, Lindner J, Treue D, Huober J, Engels K, et al. Journal article Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024 (2024) Thill M, Janni W, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, et al. Journal article, Review article Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) (2024) Meyer-Wilmes P, Huober J, Untch M, Blohmer JU, Janni W, Denkert C, Klare P, et al. Journal article Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024. (2024) Park-Simon TW, Müller V, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, Budach W, et al. Journal article, Review article